Alterity Therapeutics (ATHE) News Today $1.61 +0.01 (+0.63%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 24 at 7:35 AM | globenewswire.comAlterity Therapeutics to Present at MST Financial WebinarJuly 19, 2024 | markets.businessinsider.comAlterity Therapeutics: ATH434-202 Phase 2 Clinical Trial Shows Positive Data In MSAJuly 19, 2024 | msn.comAlterity stock climbs 8% on positive Phase 2 data for ATH434-202July 17, 2024 | globenewswire.comAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJuly 17, 2024 | globenewswire.comAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJune 12, 2024 | globenewswire.comAlterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' WebinarMay 29, 2024 | globenewswire.comAlterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyMay 8, 2024 | globenewswire.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewApril 30, 2024 | globenewswire.comAppendix 4C – Q3 FY24 Quarterly Cash Flow ReportApril 29, 2024 | finance.yahoo.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaApril 29, 2024 | globenewswire.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaApril 17, 2024 | finance.yahoo.comAlterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 10, 2024 | globenewswire.comAlterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024April 5, 2024 | finance.yahoo.comAlterity Therapeutics Limited (ATHE)March 26, 2024 | globenewswire.comAlterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundMarch 24, 2024 | morningstar.comAlterity Therapeutics Ltd ADR ATHEMarch 22, 2024 | seekingalpha.comATHE Alterity Therapeutics LimitedMarch 22, 2024 | wsj.comAlterity Therapeutics Ltd. ADRFebruary 23, 2024 | msn.comAlterity Therapeutics drops on capital raiseFebruary 22, 2024 | benzinga.comAlterity Therapeutics Stock (NASDAQ:ATHE), Short Interest ReportFebruary 21, 2024 | marketbeat.comTrading was temporarily halted for "ATHE" at 05:02 PM with a stated reason of "News pending."February 20, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | globenewswire.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingJanuary 29, 2024 | finance.yahoo.comAlterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekJanuary 22, 2024 | finance.yahoo.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesDecember 21, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressDecember 4, 2023 | marketwatch.comAlterity Therapeutics Shares Up Fivefold on New Parkinson's Drug DataDecember 4, 2023 | msn.comWhy Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?December 4, 2023 | finance.yahoo.comBiotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNovember 27, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNovember 22, 2023 | finance.yahoo.comAlterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The MomentNovember 22, 2023 | msn.comAlterity Therapeutics, Edesa Biotech among healthcare moversNovember 22, 2023 | marketwatch.comAlterity Therapeutics ADRs Shares Dive 31% on Raised CapitalNovember 20, 2023 | marketbeat.comTrading was temporarily halted for "ATHE" at 06:11 AM with a stated reason of "News pending."November 16, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434November 16, 2023 | finance.yahoo.comAlterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434November 8, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyOctober 30, 2023 | finance.yahoo.comAppendix 4C – Q1 FY24 Quarterly Cash Flow ReportAugust 31, 2023 | finance.yahoo.comAlterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderAugust 23, 2023 | finance.yahoo.comAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’sAugust 22, 2023 | technews.tmcnet.comAlterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement DisordersAugust 22, 2023 | finance.yahoo.comAlterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement DisordersAugust 15, 2023 | finance.yahoo.comAlterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundJuly 31, 2023 | finance.yahoo.comAppendix 4C – Q4 FY23 Quarterly Cash Flow ReportJuly 26, 2023 | finance.yahoo.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedJune 21, 2023 | finance.yahoo.comAlterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023May 30, 2023 | finance.yahoo.comAlterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderMay 19, 2023 | finance.yahoo.comAlterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023 Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address J.P. Morgan’s DIRE Warning (Ad)When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell." Click here to see why Wall Street is in PANIC mode >>> ATHE Media Mentions By Week ATHE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHE News Sentiment▼0.520.62▲Average Medical News Sentiment ATHE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHE Articles This Week▼30▲ATHE Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VYNE News Today NKGN News Today RVPH News Today ZIVO News Today ACST News Today SRZN News Today OCX News Today NRXP News Today MEIP News Today BCLI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.